

# Cellular exploration of childhood cancers

Shazia Begum, Joanna Denbigh, Anna Akinshina



# Introduction

#### What?

 Rhabdoid tumours are a rare form of childhood affecting young children under the age of 1 years old.

#### Where?

 They can occur anywhere in the body with the most common sites being the kidneys, soft tissue and the brain.

#### Survival?

 This cancer is difficult to cure, and the survival is poor with only 31% of those who are diagnosed living to the age of 1 years old.

#### Soft tissue - Neck



Kidnev







#### **Treatments**

- Chemotherapy and radiation therapy are very aggressive and highly toxic to young children
- o Chemotherapy drugs, that target rapidly dividing cancer cells, also damage healthy cells in children.
- o Results in many short-and long-term side effects such as heart problems, brain disorders and learning difficulties.
- o Therefore, there is a need for less toxic treatments for children.

#### **Drug repurposing**

New uses for existing drugs

#### Carvacrol

- Monoterpene phenol
- o Found in aromatic plants such as oregano and thyme





- o 2<sup>nd</sup> generation antihistamine medication
- Used for hav fever, hives and other skin allergies





## carvacrol (pink) permeates into and affects any membrane and loratadine (black) permeates cancer membrane but not the normal ones.


Simulation results show that

- o Experimental results show that the drugs kill cancer cells and not healthy cells.
- o The drugs show a synergistic used when combination, so the combined effect of the drugs was better than that produced individually.


Isobologram

LOR







Distance from bilayer centre (nm)





Normal membrane



**Drug combination** 







# Methodology

#### **Experimental approaches**

- Cell culture
- Cell toxicity experiments

# **Computational approaches**

- Molecular modelling
- o Atomistic molecular modelling of the model membranes and drugs



# **Conclusions**

- These findings suggest and reiterate the potential benefits repurposing of already approved drugs for the treatment of childhood RT.
- o Cancer membrane is more fluid and permeable for both drugs
- Combination of drugs has shown synergy.

### References

Askins, M. A., & Moore, B. D., 3rd. (2008). Preventing neurocognitive late effects in childhood cancer survivors. Journal of child neurology, 23(10), 1160-1171. doi:10.1177/0883073808321065 Brennan, B., Stiller, C., & Bourdeaut, F. (2013). Extracranial rhabdoid tumours: what we have learned so far and future directions. Lancet Oncol, 14(8), e329-336. doi:10.1016/S1470-2045(13)70088-3